Cargando…
Toxic Epidermal Necrolysis and Stevens - Johnson Syndrome Following Sintilimab Administration in a Non-Small Cell Lung Cancer Patient: A Case Report
Immune checkpoint inhibitors such as monoclonal antibodies have been used recently with greater effect for the management of non-small cell lung cancer (NSCLC). Sintilimab, a fully human IgG4 monoclonal antibody is specific for the immune checkpoint protein programmed cell death receptor-1 (PD-1). I...
Autores principales: | Jiang, Ziyu, Chen, Xiaoli, Sun, Zhaoshen, Shen, Xiaowei, Huang, Yaju, Liu, Jingbing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10627061/ https://www.ncbi.nlm.nih.gov/pubmed/37936597 http://dx.doi.org/10.2147/JIR.S427336 |
Ejemplares similares
-
Toxic epidermal necrolysis and Stevens-Johnson syndrome
por: Harr, Thomas, et al.
Publicado: (2010) -
Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis
por: Klimas, Natasha, et al.
Publicado: (2015) -
Stevens–Johnson syndrome/toxic epidermal necrolysis associated with zonisamide
por: Vivar, Karina L., et al.
Publicado: (2017) -
The Epidemiology of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in China
por: Yang, Shang-Chen, et al.
Publicado: (2018) -
Ampicillin/sulbactam: Stevens-Johnson syndrome/toxic epidermal necrolysis
Publicado: (2021)